- Atossa Genetics (ATOS) Opens Enrollment for Fulvestrant Phase 2 in Breast Cancer
- Atossa Genetics Inc. (Nasdaq: ATOS) announced today that the "007" trial, a Phase 2 study in women with ductal carcinoma in situ (DCIS) or invasive breast cancer slated for mastectomy, is open for enrollment.
- Atossa Genetics Inc (NASDAQ:ATOS) Explodes Up The Charts
- Shares of Atossa Genetics Inc (NASDAQ:ATOS) have exploded up the charts recently on news of insider buying and optimism for upcoming clinical trial updates. Shares have also put in a critical double bottom and the lows look to be in on the stock.
- The President & CEO of Atossa Genetics (NASDAQ: ATOS) is Buying Shares
- Currently, Atossa Genetics has an average volume of 1.09M. Atossa Genetics Inc is a healthcare company.
- Atossa Genetics Incorporated (NASDAQ:ATOS) Shorted Shares Decreased By 17.61%
- The stock of Atossa Genetics Incorporated (NASDAQ:ATOS) registered a decrease of 17.61% in short interest. ATOS's total short interest was 221,700 shares in March as published by FINRA.
- Atossa Genetics Incorporated (NASDAQ:ATOS) Shorted Shares Increased 45.54
- The stock of Atossa Genetics Incorporated (NASDAQ:ATOS) registered an increase of 45.54% in short interest. ATOS's total short interest was 269,100 shares in February as published by FINRA.
Atossa is described in multiple online sources, as addition to our editors' articles, see section below for printable documents, Atossa books and related discussion.
Suggested News Resources
Great care has been taken to prepare the information on this page. Elements of the content come from factual and lexical knowledge databases, realmagick.com library and third-party sources. We appreciate your suggestions and comments on further improvements of the site.
Related searchespolar molecule
infant the newborns senses
beat the clock
mahjong international rules
prostate cancer pathophysiology
eurovelo eurovelo 6